CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Autolus' obe-cel shows sustained responses in Phase 1 trial for severe lupus

By Public Technologies
  • Autolus Therapeutics presented longer-term Phase 1 CARLYSLE results for obe-cel in severe refractory systemic lupus erythematosus at ACR Convergence 2026.
  • Most participants achieved disease remission despite severe baseline disease; kidney responses were observed without severe renal flares.
  • Obe-cel was well tolerated in 15 patients, with no severe cytokine release syndrome or specified neurological and inflammatory complications observed.
  • Follow-up extended to 25 months in adults; the therapy is being evaluated in the Phase 2 LUMINA trial for lupus nephritis.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Autolus Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611101605PRIMZONEFULLFEED9874314) on November 10, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk